PharmacoEconomics & Outcomes News

, Volume 799, Issue 1, pp 4–4 | Cite as

ICER updates price benchmark for PCSK9 inhibitor, alirocumab

News item


  1. Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Updates Value-Based Price Benchmark for Alirocumab, a PCSK9 Inhibitor for Treatment of High Cholesterol. Internet Document : 10 Mar 2018. Available from: URL:

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations